What the business is, and whether it's a good one at a fair price.
Markets and sells insulin and other diabetes therapies in India, anchored on Lantus, Toujeo and the fixed-dose combination Soliqua. Alongside the diabetes franchise, the company distributes a legacy portfolio of cardiovascular, CNS and oral anti-diabetic brands through partnership agreements, with management describing this as the second pillar of a transformed business model. Public-sector expansion into CGHS, ESI, railways, defence and state rate contracts is a stated growth lever, alongside Tier 2/3 city penetration. Exports are a residual line — they collapsed after the 2020 divestment of the Ankleshwar manufacturing site to Zentiva, with Russia and South Africa now partially offsetting the gap; management says exports are only ~8% of PBT. No new product launches are planned for 2026; the development pipeline referenced is Teizeild, Brivekimig and Frexalimab. Costs are dominated by personnel and operating expenses, with FY26 opex down 17% on a partnership-driven restructuring tied to the Emcure deal.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY24 — not investment advice
Not enough history to assess.How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SANOFI INDIA LIMITED's filed financials and exchange disclosures
SANOFI INDIA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SANOFI.
Yes. Over the trailing twelve months SANOFI INDIA LIMITED reported a net profit of ₹413 Cr on revenue of ₹2,235 Cr.
Effectively yes. It holds ₹284 Cr more cash than debt.
On trailing P/E, SANOFI INDIA LIMITED ranks 46 of 169 in Pharmaceuticals — cheaper than 73% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SANOFI INDIA LIMITED moves 0.68% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SANOFI INDIA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
